TRANSCRANIAL DOPPLER SIMULATOR FOR TRAINING AND ASSESSMENT

我们的目标是开发一个经颅多普勒（TCD）超声模拟器上的物理 人体模型用于现实医学培训和专业能力测试。的 该项目的具体目标是： 1.开发TCD模拟器原型。脑血管系统的解剖学 (CVS)将从患者的计算机三维（3D）重建 断层血管造影（CTA）。CVS内各点的血流速度将 使用计算流建模来定义，并用于生成多普勒 TCD的频谱波形模拟。 2.通过生成2D B- 模式超声图像从CTA。彩色多普勒图像将在 与我们的血管多普勒模拟器一样，从血流模型中获得真实的时间。 3.通过比较测量的血流速度来验证模拟的准确性 从模拟器波形与3D模型中的真实速度。我们将核实 通过比较频谱多普勒波形， 使用患者多普勒频谱波形在模拟器上测量。 这项研究将通过扩大患者对中药的使用， 推荐的诊断程序，通过帮助增加供应商的数量 接受过TCD治疗更广泛地使用基于证据的TCD应用将有助于 避免侵入性和更昂贵的替代诊断测试。本研究是 适用于缺医少药的患者--镰状细胞病患者--和大规模的 因为中风是美国人死亡的第五大原因， TCD在缺血性和出血性脑血管病的治疗中具有重要应用 中风

We aim to develop a transcranial Doppler (TCD) ultrasound simulator on a physical mannequin for realistic medical training and professional competence testing. The Specific Aims of the project are: 1. Develop a prototype TCD simulator. The anatomy of the cerebrovascular system (CVS) will be reconstructed in three dimensional (3D) from a patient’s computed tomography angiogram (CTA). The blood flow velocity at points within the CVS will be defined using computational flow modeling and used to generate the Doppler spectral waveform simulation for the TCD. 2. Develop a prototype transcranial color Doppler simulator by generating 2D B- mode ultrasound images from the CTA. Color Doppler images will be generated in real time from the flow model as in our vascular Doppler simulator. 3. Verify the accuracy of the simulation by comparing blood flow velocity measured from the simulator waveforms with the true velocities in the 3D models. We will verify the clinical realism of the simulation by comparing spectral Doppler waveforms measured on the simulator with patient Doppler spectral waveforms. This research will benefit health care by expanding patient access to TCD, a recommended diagnostic procedure, by helping to increase the number of providers trained to perform TCD. Wider use of evidence based applications of TCD will help avoid invasive and more expensive alternative diagnostic tests. This research is applicable both to underserved patients – those with sickle cell disease -- and to large patient populations because stroke is the fifth leading cause of death for Americans and TCD has critical applications in the management of ischemic as well as hemorrhagic strokes.